6826.HK Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (28 birž. 2024 @ 11:08):
Our systems believe the stock currently is overvalued by -0.07% compare to its pairs and should correct downwards.

Stats
Šios dienos apimtis	488 100
Vidutinė apimtis	133 598
Rinkos kapitalizacija	14.86B
EPS	HKD0.580 ( Q1 \| 2024-03-31 )
Kita pelno data	( HKD0 ) 2024-08-14
Last Dividend	HKD0.441 ( 2023-07-04 )
Next Dividend	HKD0 ( N/A )
P/E	16.31 (Sector) 14.27 (Industry) 6.31
ATR14	HKD0.112 (0.35%)

0690.HK 0.00%

1061.HK -0.82%

1167.HK 3.31%

1177.HK -1.11%

1228.HK 0.00%

1477.HK 1.63%

1521.HK -2.44%

1530.HK 2.71%

1548.HK -1.42%

1672.HK -3.61%

1873.HK 0.00%

1875.HK -0.45%

1877.HK -0.51%

1952.HK -2.59%

2096.HK -0.69%

2126.HK -2.00%

2137.HK -0.98%

2142.HK 1.47%

2157.HK -3.80%

2162.HK -2.88%

2171.HK -2.04%

2179.HK -3.00%

2197.HK -1.45%

2256.HK -0.61%

2257.HK 0.00%

2616.HK 2.70%

2696.HK -0.65%

3759.HK -1.63%

6160.HK 1.17%

6600.HK 0.86%

6622.HK 0.71%

6628.HK 1.33%

6821.HK -0.10%

6826.HK 1.76%

6978.HK 23.00%

6996.HK 0.00%

6998.HK 0.00%

9688.HK -0.15%

9926.HK -2.33%

9939.HK -4.59%

9966.HK -0.41%

9969.HK 3.66%

9995.HK -4.67%

Koreliacija (AI algo v.1.1b): Overvalued: -0.07% HKD31.82 paired level. (Algoritmas realiuoju laiku stebi didžiausią koreliaciją turinčių akcijų pokyčius ir suteikia momentinę informaciją)

Tūris Koreliacija

Ilgas: -0.02 (neutral)

Trumpas: -1.00 (very strong negative)

Signal:(34.764) Neutral

Shanghai Haohai Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Shanghai Haohai Koreliacija - Valiuta/Žaliavos

0.80
( moderate )

0.55
( weak )

0.70
( moderate )

0.77
( moderate )

0.23
( neutral )

-0.62
( weak negative )

Shanghai Haohai Finansinės ataskaitos

Annual	2023
Pajamos:	HKD2.63B
Bruto pelnas:	HKD1.85B (70.34 %)
EPS:	HKD2.44

FY	2023
Pajamos:	HKD2.63B
Bruto pelnas:	HKD1.85B (70.34 %)
EPS:	HKD2.44

FY	2022
Pajamos:	HKD2.10B
Bruto pelnas:	HKD1.45B (68.79 %)
EPS:	HKD1.040

FY	2021
Pajamos:	HKD1.75B
Bruto pelnas:	HKD1.26B (71.98 %)
EPS:	HKD2.16

Financial Reports:

No articles found.

Shanghai Haohai Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0.820 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0.441 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

Shanghai Haohai Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 6.57 - Stable (31.36%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.472	2016-06-08
Last Dividend	HKD0.441	2023-07-04
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	8	--
Total Paid Out	HKD4.88	--
Avg. Dividend % Per Year	0.00%	--
Score	3.42	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	6.57
Div. Directional Score	9.47	--

Next Divdend (Est)
(2024-07-12)

HKD0.326 Estimate 3.08 %

Dividend Stability

0.25 Very Poor

Dividend Score

3.42

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Dividend History

Ex Date	Amount	Declaration Date	Record Date	Payment Date
04 Jul 2023	HKD0.441	30 Nov -0001	30 Nov -0001	30 Nov -0001
29 Jul 2022	HKD0.820	30 Nov -0001	30 Nov -0001	30 Nov -0001
15 Jul 2021	HKD0.606	30 Nov -0001	30 Nov -0001	30 Nov -0001
02 Jul 2020	HKD0.766	30 Nov -0001	30 Nov -0001	30 Nov -0001
14 Mar 2019	HKD0.585	30 Nov -0001	30 Nov -0001	30 Nov -0001
19 Jun 2018	HKD0.612	30 Nov -0001	30 Nov -0001	30 Nov -0001
29 Jun 2017	HKD0.573	30 Nov -0001	30 Nov -0001	30 Nov -0001
08 Jun 2016	HKD0.472	30 Nov -0001	30 Nov -0001	30 Nov -0001

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
1821.HK	Ex Dividend Junior	2023-09-07	Semi-Annually	0.00%
0163.HK	Ex Dividend Junior	2023-09-26	Semi-Annually	0.00%
9983.HK	Ex Dividend Junior	2023-09-18	Semi-Annually	0.00%
1268.HK	Ex Dividend Knight	2023-09-20	Semi-Annually	0.00%
3600.HK	Ex Dividend Knight	2023-09-12	Annually	0.00%
0817.HK	Ex Dividend Junior	2023-09-18	Semi-Annually	0.00%
2003.HK	Ex Dividend Junior	2023-10-17	Annually	0.00%
0375.HK	Ex Dividend Knight	2023-09-27	Annually	0.00%
1516.HK	Ex Dividend Junior	2023-09-27	Annually	0.00%
0035.HK	Ex Dividend Knight	2023-09-05	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.162	1.500	6.76	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0601	1.200	8.00	9.59	[0 - 0.3]
returnOnEquityTTM	0.0758	1.500	-0.269	-0.403	[0.1 - 1]
payoutRatioTTM	0.00467	-1.000	9.95	-9.95	[0 - 1]
currentRatioTTM	5.43	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	4.43	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	3.88	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.0296	-1.500	9.51	-10.00	[0 - 0.6]
interestCoverageTTM	52.94	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	3.37	2.00	8.88	10.00	[0 - 30]
freeCashFlowPerShareTTM	1.049	2.00	9.48	10.00	[0 - 20]
debtEquityRatioTTM	0.0370	-1.500	9.85	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.698	1.000	1.699	1.699	[0.2 - 0.8]
operatingProfitMarginTTM	0.177	1.000	8.46	8.46	[0.1 - 0.6]
cashFlowToDebtRatioTTM	2.67	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.371	0.800	-0.859	-0.687	[0.5 - 2]
Total Score				12.36

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	11.54	1.000	8.94	0	[1 - 100]
returnOnEquityTTM	0.0758	2.50	-0.173	-0.403	[0.1 - 1.5]
freeCashFlowPerShareTTM	1.049	2.00	9.65	10.00	[0 - 30]
dividendYielPercentageTTM	5.20	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	3.37	2.00	8.88	10.00	[0 - 30]
payoutRatioTTM	0.00467	1.500	9.95	-9.95	[0 - 1]
pegRatioTTM	0.819	1.500	7.88	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.213	1.000	7.18	0	[0.1 - 0.5]
Total Score				6.57

Shanghai Haohai Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Shanghai Haohai

Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in Mainland China, the United States, the United Kingdom, and internationally. It offers ophthalmology products comprising intraocular lens, ophthalmic viscoelastic devices, orthokeratology and phakic refractive lenses, eye drops, injectors, scalpels, etc.; orthopedics products, such as sodium hyaluronate injection and medical chitosan; wound repair products, including recombinant human epidermal growth factor for the treatment of burn wound, residual wound, donor site posttraumatic wound, and fresh or old wound of chronic ulcer; anti-adhesion materials comprising medical sodium hyaluronate gel and medical chitosan; and hemostatic materials, such as collagen sponge and porcine fibrin sealants. The company also provides medical aesthetics products comprising Matrifill, a first-generation HA dermal filler, which is a mono-phase sodium hyaluronate gel for injection; Janlane, a second-generation HA dermal filler for dynamic filling function; Hyalumatrix, a third-generation HA dermal filler that offers precise embellishment function; and radio frequency devices and laser equipment. In addition, it is involved in research and development of biological engineering and pharmaceutical products, as well as in the provision of related technology transfer, and consultation services; and investment and trading business. The company was formerly known as Haohai Limited and changed its name to Shanghai Haohai Biological Technology Co., Ltd. in 2010. Shanghai Haohai Biological Technology Co., Ltd. was founded in 2007 and is headquartered in Shanghai, China.